Element Biosciences

About

Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets.

San Diego,California,United States
101 - 250
https://www.elementbiosciences.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $15M
Industries: Biotechnology,Genetics,Health Diagnostics,Life Science
Founded date: Jul 7, 2017
Number Of Employee: 101 - 250
Operating Status: Active
Legal Name: Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets.
We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible.
Our proprietary approach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$401M

Element Biosciences has raised a total of $401M in funding over 2 rounds. Their latest funding was raised on Jun 29, 2021 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 29, 2021	Series C	$276M	10	Venrock	—	Detail
Jun 26, 2020	Series B	$30M	2	—	—	Detail
Jan 9, 2020	Series B	$80M	4	—	—	Detail
Jun 18, 2019	Series A	$15M	2	Foresite Capital Venrock	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

12

Element Biosciences is funded by 12 investors. Venrock and Counterpoint Global are the most recent investors.

Investor Name	Lead Investor	Funding Round
Venrock	Yes	Series C
Counterpoint Global	—	Series C
Fidelity Management and Research Company	—	Series C
Foresite Capital	—	Series C
Janus Henderson Investors	—	Series C
JS Capital Management	—	Series C
Logos Capital	—	Series C
Meritech Capital Partners	—	Series C
RA Capital Management	—	Series C
T. Rowe Price	—	Series C